In order to evaluate an x-fold increase in TGFβ1-triggered expression of αSMA (CMHDF, rTGFβ1; CMSCL) in comparison with mock-treatment (CMHDF), subconfluent HDF were treated with recombinant- and tumour cell-derived TGFβ1. This evidence concerns the gene TGFB1 and neoplasm.